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1. Introduction 
Despite of being described more than one decade ago (Pittenger et al., 1999), the 
immunophenotypic profile of bone marrow mesenchymal stem cells (MSC) still not well 
documented. The difficulty in achieving a detailed phenotypic characterization is common 
in less-represented cell populations and/or populations lacking a specific known cell 
marker, like bone marrow MSC. 
The recent advances in flow cytometry technology and the emergence of new high-speed 
flow cytometers have given a valuable contribute to diminish this problem in two different 
(but complementary) aspects: 1) by reducing dramatically the acquisition time period, 
making it more reasonable to study minor cell populations; and 2) by increasing the number 
of parameters that can be analyzed per cell at the same time, which is critical to improve the 
immunophenotypic characterization of those not-well characterized cell populations that 
lack a specific known marker. 
A good example of the practical usefulness of such technical developments is the 
description of different cell compartments in the bone marrow CD34+ hematopoietic stem 
cell (HSC) population. Detailed studies on this minor bone marrow cell population 
demonstrated that each compartment is committed to a different hematopoietic cell lineage. 
An extensive immunophenotypic characterization of those CD34+ compartments allowed 
the development of protocols to easily and quickly identify, quantify and evaluate 
phenotypic aberrations and maturational blocks in those cells, which is decisive to the 
diagnosis, prognosis, or follow-up of a variety of hematological clonal diseases (del Cañizo 
et al., 2003; Lochem et al., 2004; Matarraz et al., 2008; Orfao et al. 2004). 
2. Bone marrow mesenchymal stem cells 
After the identification of a plastic-adherent bone marrow stromal cell population in 1976 by 
Friedenstein and colleagues and the first evidence of their multilineage potential (Pittenger 
et al., 1999) with subsequent confirmation of their stem cell nature, an increasing interest on 
these bone marrow MSC has emerged, mainly because of their promising therapeutic 
applications. 
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By definition, a stem cell is an undifferentiated cell with the potential ability of self-renewal 
and the capability of differentiation along different cell lineages (multipotency). MSC can be 
found on a great variety of adult tissues, where they play an important role in tissue 
regeneration, such as: bone marrow, adipose tissue, umbilical cord blood, umbilical cord 
matrix, menstrual blood, endometrium, placenta, dental pulp, skin and thymus, among 
others (Chamberlain et al., 2007; Ding et al. 2011; Kolf et al., 2007; Martins et al., 2009; 
Musina et al., 2005; Pittenger et al., 1999). 
In addition to their presence in numerous adult tissues, MSC are relatively easy to isolate 
and have the capability to expand manyfold in culture without lose their stem cell properties. 
Moreover, when MSC are systemically transplanted, they are able to migrate to sites of injury 
and promote tissue repair, by producing growth factors or other soluble factors important to 
tissue regeneration, as well as by undergoing cellular differentiation (Chamberlain et al., 
2007, Kolf et al., 2007; Mafi et al., 2011); such features explain the success of MSC transfusion 
therapy in genetic disorders affecting mesenchymal tissues (Horwitz et al., 2002; Undale et 
al., 2009). Furthermore, those cells have the ability of suppressing the immune response of a 
wide variety of immune cells, including T, B and NK  lymphocytes, and antigen-presenting 
cells (Chamberlain et al., 2007; Stagg, 2007), and their importance in patients’ clinical 
outcome has already been proven in severe acute graft-versus-host disease (Remberger et 
al., 2011; von Bahr et al., 2011). Moreover, the results achieved in animal models of 
autoimmune diseases are promising and encouraged the beginning of phase I clinical trials 
in multiple sclerosis (Constantin et al., 2009; Darlington et al., 2011; Siatskas et al., 2009). 
2.1 Identification and quantification of bone marrow MSC 
As referred previously, the study of minor cell populations with no known specific cell 
marker toke great advantage on the development of high-speed multi-parameter flow 
cytometers. The use of an 8-color FACSCanto II (Becton Dickinson Biosciences, BDB) flow 
cytometer allowed us to identify MSC in bone marrow, quantify them and further 
characterize their immunophenotypic profile. We employed a monoclonal antibody panel 
with a backbone of 3 common markers (CD13, CD45 and CD11b) for the identification of 
MSC (known to be CD13+CD45-CD11b-) in each tube that, at the same time, permitted the 
study of the expression of five more proteins on MSC per tube. 
MSC are rare in bone marrow, being reported that they represent approximately 0,01% of all 
nucleated bone marrow cells (Chamberlain et al., 2007; Mafi et al., 2011), although is known 
that their number declines with aging (Caplan, 2007). Our data point to a percentage 
ranging between 0,01% and 0,03% of all nucleated bone marrow cells (Martins et al., 2009). 
2.2 Immunophenotypic characterization of bone marrow MSC 
2.2.1 Flow cytometer quality control, compensation setup strategies and other 
technical issues 
According to the manufacturer’s recommendations, it is done a daily quality control using 
the Rainbow Beads (BDB). In what concerns to cytometer’s compensation setup, it is made 
once per month by setting up the Rainbow Beads (BDB) values according to the EuroFlow 
consortium’s guidelines and then by doing a general compensation for stable fluorochromes 
and a specific compensation for each monoclonal antibody conjugated with tandem 
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fluorochromes. Although the compensation is automatic, it is always revised by experienced 
staff at the end of the process. 
In order to detect cellular autofluorescence, a negative control was made for each sample, 
where the bone marrow sample was only stained for CD45 PO and CD34 PerCPcy5.5. 
SSC and FSC light dispersion properties allow a good discrimination between viable and 
dead cells and the doublets were excluded based on FSC-Area versus FSC-Height 
characteristics. 
2.2.2 Material and methods 
The immunophenotypic characterization of bone marrow MSC were performed in fresh 
EDTA-collected bone marrow samples from healthy individuals. After collection the 
samples were stored at 4 ºC and processed within 24 hours. 
Whole bone marrow samples were stained for surface cell markers using a stain-lyse-and-
then-wash direct immunofluorescence technique. 200 μl of whole bone marrow were 
aliquoted in different tubes and stained with the following combinations of monoclonal 
antibodies in an 8-color staining protocol, detailed in table 1. 
 
 
FITC PE PerCPcy5.5 PEcy7 APC APCH7 PB PO 
Tube 
1 
CD49e 
(SAM1) 
Beckman 
Coulter 
CD73 
(AD2) 
BD 
Pharmingen
CD34 
(8G12) 
BDB 
CD13 
(Immu103.44)
Beckman 
Coulter 
CD90 
(5E10) 
BD 
Pharmingen
HLA-DR 
(L243) 
BDB 
CD11b 
(ICRF44) 
BD 
Pharmingen 
CD45 
(HI30) 
Invitrogen 
Tube 
2 
CD31 
(WM59) 
BD 
Pharmingen 
NGFR 
(C40-1457) 
BD 
Pharmingen
CD14 
(M5E2) 
BD 
Pharmingen
CD13 
CD133 
(293C3) 
Miltenyi 
Biotec 
- CD11b CD45 
Tube 
3 
CD15 
(HI98) 
BDB 
CD146 
(P1H12) 
BD 
Pharmingen
CD24 
(ALB9) 
Beckman 
Coulter 
CD13 CD90 
CD29 
(TS2/16) 
BioLegend
CD11b CD45 
Tube 
4 
CD106 
(51-10C9) 
BD 
Pharmingen 
CD105 
(1G2) 
Beckman 
Coulter 
- CD13 
HLA-A, B, C
(G46-2.6) 
BD 
Pharmingen
- CD11b CD45 
Tube 
5 
- CD73 CD24 CD13 CD90 - CD11b CD45 
Table 1. Panel of monoclonal antibodies used for the bone marrow MSC characterization. 
FITC - fluorescein isothiocyanate; PE – phycoerythrin; PerCPcy5.5 - peridinin chlorophyll 
protein cyanine 5.5; PEcy7 - R-phycoerythrin cyanine 7; APC – allophycocyanin; APCH7 - 
allophycocyanin H 7; PB - pacific blue; PO - pacific orange 
Data acquisition was performed in a FACSCanto II flow cytometer (BDB), using FACSDiva 
acquisition software (BDB). The total bone marrow cellularity of the whole sample was 
acquired (5 x 106 events, minimum) for each tube. Bone marrow MSC were identified as 
CD13+/CD45-/CD11b-, as shown in Figure 1. 
Data analysis was performed using Infinicyt software (Cytognos, Salamanca, Spain). 
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Fig. 1. Identification of bone marrow MSC (blue) present in a whole bone marrow sample, 
phenotypically characterized as CD13+CD45-CD11b- 
2.2.3 Results and discussion 
Bone marrow MSC showed to be uniformly positive to CD13, CD29, CD49e, CD90, CD106, 
CD146, CD73, NGFR, CD105 and HLA-A, B, C (Figure 1 and Figure 2); and negative to 
CD24, CD31, CD11b, CD14, CD15, CD34, CD45, CD133 and HLA-DR, which is in agreement 
with previous studies described in the literature (Chamberlain et al., 2007; Delorme et al., 
2008; Ehninger & Trumpp, 2011; Fox et al., 2007; Jones & McGonagle, 2008; Kolf et al., 2007; 
Martins et al., 2009; Pittenger et al., 1999; Tormin et al., 2011). Based on the expression 
profile of these markers, bone marrow MSC behave as one sole cell population, as all the 
studied markers were homogeneously expressed inside the MSC population. 
Several studies on adhesion molecules and chemokine receptors expression have been made 
in order to shed light on MSC migratory and homing ability. CD29 (integrin β1-subunit) and 
CD106 (vascular cell adhesion molecule 1, VCAM-1) seem to be important in the adhesion of 
MSC to endothelial cells (Chamberlain et al., 2007; Kolf et al., 2007; Stagg, 2007) and CD29, 
which when dimerized with CD49e (integrin α5-subunit) forms a receptor that binds to 
fibronectin and invasin, is likely to promote MSC-extracellular matrix interaction (Gu et al., 
2009). CD146 (Muc18) plays an important role in cell-cell and cell-extracellular matrix 
adhesion and an increased expression of these marker on tumor cells is associated with an 
increased cell motility and invasiveness/ metastasis capability (Bardin et al., 2001; Zeng et 
al., 2011). The glycoprotein CD90 (Thy-1) regulates as well cell-cell and cell-extracellular 
matrix interactions, being involved in adhesion to endothelial cells, migration, metastasis 
and tissue regeneration (Jurisic et al., 2010; Rege & Hagood, 2006). 
The enzyme CD73 is an ecto-5’-nucleotidase that produces extracellular adenosine. In 
animal tumor models, CD73-generated adenosine inhibits both homing and expansion of T 
cells via adenosine-receptor signaling. In fact, recent research shows that adenosine 
suppresses T cell immune response both in activation and effector phases, as well as NK cell 
immune activity (Wang et al., 2011; Zhang et al., 2010). 
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Fig. 2. Immunophenotypic characteristics of bone marrow MSC (blue). The remaining bone 
marrow nucleated cells are represented as grey events 
In what concerns to growth factor receptors, NGFR (nerve growth factor receptor, CD271) is 
expressed in a wide variety of tissues and, depending on the cell type, signaling through 
this receptor regulates NF-kB activation, apoptosis, tissue regeneration, immune cell 
activation, proliferation and cell differentiation (Micera et al., 2007; Rogers et al., 2010). 
Finally, CD105 (endoglin) is one of the receptors for TGF-β, a growth factor involved in the 
regulation of development, maintenance and proliferation of MSC (Stagg, 2007), and also 
known to play an important role in tissue repair. 
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Some discrepancies described in the expression of adhesion molecules, chemokine receptors 
and other proteins, may be the reflex of the microenvironmental differences present in 
different studies. Although there are a great similitude in the phenotypic profile of MSC 
isolated from different tissues, differences do exist (Chamberlain et al., 2007; Kolf et al., 2007; 
Martins et al., 2009). As well as different cultures conditions can also change the MSC 
phenotype (Chamberlain et al., 2007; Halfon et al., 2011; Stagg, 2007; Tormin et al., 2011). 
This could be a clue of MSC highly sensitiveness to microenvironment alterations, and their 
potential to change their protein expression profile could be of great importance in giving an 
appropriate response to physiological or pathological challenges: by changing their 
migratory pattern, by initiating an immunomodulatory or immunosuppressive response, by 
modifying the production and release of soluble factors, or by undergoing cell 
differentiation. 
As a minor bone marrow cell population easy to expand in vitro, it is attractive to 
characterize the MSC immunophenotype after culture cell expansion. Nevertheless, 
characterizing these cells directly (without previous culture) enables an analysis closest to 
their physiological conditions, excluding the phenotypic alterations induced by factors 
present in the culture medium. Moreover, this direct approach allows an accurate 
quantification of MSC in bone marrow. Also, this same strategy can be applied to MSC from 
other tissues. 
3. Bone marrow hematopoietic stem cells  
The multipotent hematopoietic stem cell is mainly located in the bone marrow of adult 
animals and has the ability to differentiate along all hematopoietic cell lineages. A number 
of studies based on in vitro cell culture, xeno-transplantation of hematopoietic human cells 
in immunodeficient mice and in pre-immune animal fetuses, were carried out to identify the 
human hematopoietic stem cell and unveil the hematopoietic precursors hierarchy (Nimer, 
2008; Yin et al., 2007), becoming clear that CD34-positive cells were able to differentiate and 
give rise to all blood cells. There are evidences that, within this heterogeneous population, 
the more immature CD34+ HSC expresses CD133 and are CD38-negative/dim. It is also 
known that the CD34+CD133+ subpopulation can arise from the CD133+CD34-CD38- 
subset (Goussetis et al., 2006; Nimer, 2008; Yin et al., 1997). 
3.1 Identification and quantification of the different bone marrow CD34+ HSC cell 
compartments 
As already referred, CD34-positive cells are an heterogeneous bone marrow cell population, 
consisting in various cell compartments differing in immunophenotype, size and lineage 
commitment. The immunophenotypic pattern of each compartment is well described and, 
with a relatively low number of markers, the majority of those subsets can be accurately and 
easily identified. 
Attending only to the immunophenotypic features, is possible to identify the following bone 
marrow CD34+ cell subsets by flow cytometry: uncommitted (more immature) precursors, 
neutrophil precursors, B cell precursors, monocytic precursors, plasmacytoid dendritic cells 
precursors, erythroid precursors, basophil precursors and mast cell precursors. 
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A detailed immunophenotypic description of human bone marrow CD34+ cells was 
published, few years ago, by Matarraz and colleagues (Matarraz et al., 2008) and Lochem 
and colleagues (Lochem et al., 2004), along with the frequency of each CD34+ cell 
subpopulation in normal hematopoiesis (Matarraz et al. 2008), presented on table 2. 
Bone marrow CD34+ HSC compartments 
Mean ± 
Standard 
deviation 
Range 
% Bone marrow CD34+ HSC 
(of total bone marrow) 
0,9 ± 0,3 (0,2-1,6) 
Immature CD34+ precursor (%) 
(within CD34+ cells) 
52 ± 12 (19-66) 
CD34+ neutrophil precursors (%) 
(within CD34+ cells) 
34 ± 7 (15-47) 
CD34+ B cell precursors  (%) 
(within CD34+ cells) 
14 ± 10 (1-36) 
CD34+ monocytic precursors (%) 
(within CD34+ cells) 
10 ± 7 (0-26) 
CD34+ plasmacytoid dendritic cell precursors (%) 
(within CD34+ cells) 
5 ± 2 (0-9) 
CD34+ erythroid precursors (%) 
(within CD34+ cells) 
18 ± 8 (1-36) 
CD34+ basophil precursors (%) 
(within CD34+ cells) 
0,7 ± 0,4 (0-1,5) 
CD34+ mast cell precursors (%) 
(within CD34+ cells) 
0 ± 0,005 (0-0,02) 
Table 2. Distribution of the different cell compartments of bone marrow CD34+ HSC. The 
results are expressed as mean ± standard deviation (range). Adapted from Matarraz et al. 
Leukemia 2008 
The most immature CD34+ subset can be identified based on CD133 expression (Goussetis 
et al., 2006; Pastore et al., 2008; Yin et al., 1997). When other markers are concerned, these 
cell are CD34hi/CD45int/HLA-DRhi/cyMPO-/nTdT-/CD117hi and have intermediate side 
scatter (SSC) and forward scatter (FSC) light dispersion properties (Matarraz et al., 2008). As 
previously described by Matarraz and colleagues, the phenotypic profile of CD34+ B cell 
precursors is CD34int/CD45int/dim/HLA-DRhi/cyMPO-/nTdTint/CD117- and these cells 
present the lowest SSC and FSC of all CD34+ subpopulations (Lochem et al., 2004; Matarraz 
et al., 2008); the CD34+ neutrophil precursors present CD34hi/CD45int/dim/HLA-
DRhi/cyMPOint/hi/nTdT-/CD117hi, along with the highest values for SSC and FSC of all 
CD34+ subsets; the CD34+ plasmacytoid dendritic cell precursors are identified based on 
the expression of CD34+/CD123hi/int/HLA-DRhi; CD34+ monocytic precursors display 
CD34+/HLA-DRhi/CD64hi/CD45hi/CD117- immunophenotype; basophil precursors are 
described as being CD34+/CD123int/hi/HLA-DR-/+; and CD34+ mast cell precursors are 
CD34+/CD117hi/HLA-DR-/int (Matarraz et al., 2008). Finally, CD34+ erythroid precursors 
are characterized by CD34+/CD36+/CD64-/CD45lo immunophenotype (Matarraz et al., 
2008) and by CD105 expression (Buhring et al., 1991; Rokhlin et al., 1995). As a matter of fact, 
CD105 and TGF-β1 have a pivotal role in the regulation of the differentiation in the 
erythroid lineage (Fortunel et al., 2000; Moody et al., 2007). 
www.intechopen.com
 
Flow Cytometry – Recent Perspectives 
 
464 
3.2 A single-tube protocol to identify the different bone marrow CD34+ HSC 
compartments 
Recently, we developed an 8-color single-tube protocol to identify the different bone 
marrow CD34+ HSC subsets by flow cytometry. 
The single-tube protocol we propose here was constructed to allow an accurate, quick and 
easy identification and quantification of those cellular compartments. Attending to the 
monoclonal antibodies and fluorochrome-conjugation available on the market and to 
compensation issues, and based on our experience and knowledge on the hematopoietic 
maturation dynamics, we elected the best markers to identify with precision the cell 
populations of interest. 
3.2.1 Material and methods 
The immunophenotypic characterization of bone marrow CD34+ precursors were 
performed in fresh EDTA-collected bone marrow samples from healthy individuals. After 
collection, the samples were stored at 4 ºC and processed within 24 hours. The quality 
control and compensation strategies are described in detail in section 2.2.1. 
A stain-lyse-and-then-wash direct immunofluorescence protocol was used, and the 
monoclonal antibodies were combined as presented on table 3. 
 
 
FITC PE 
PerCPcy
5.5 
PEcy7 APC APCH7 PB PO 
Single 
Tube 
Protocol 
CD35 
(E11) 
BDB 
Pharmingem
CD123 
(SSDCL
Y107D2)
Beckman 
Coulter 
CD34 
(8G12) 
BDB 
CD117 
(PN 
IM3698) 
Beckman 
Coulter 
CD133 
(293C3) 
Miltenyi 
Biotec 
HLA-DR 
(L243) 
BDB 
CD44 
(IM7) 
Biolegend 
CD45 
(HI30) 
Invitrogen 
FITC - fluorescein isothiocyanate; PE – phycoerythrin; PerCPcy5.5 - peridinin chlorophyll protein 
cyanine 5.5; PEcy7 - R-phycoerythrin cyanine 7; APC – allophycocyanin; APCH7 - allophycocyanin H 7; 
PB - pacific blue; PO - pacific orange. 
Table 3. Panel of monoclonal antibodies used for the identification and quantification of the 
different subpopulations found in bone marrow CD34+ HSC 
Data acquisition was performed on a FACSCanto II flow cytometer (BDB), using FACSDiva 
acquisition software (BDB). In a first step of acquisition, the whole bone marrow cellularity 
was stored (100.000 events). In a second step, only events within the CD34+ electronic gate 
were acquired (5.000 to 10.000 CD34+ events). 
Data analysis was performed using Infinicyt software (Cytognos, Salamanca, Spain). 
3.2.2 How to identify the different CD34+ HSC compartments with the single-tube 
protocol? 
1. The most immature (uncommitted) compartment of bone marrow C34+ HSC 
The most immature compartment can be easily identified based on their positivity to 
CD133 marker (CD133hi). To differentiate this subset from CD34+ neutrophil precursors 
and CD34+ plasmacytoid dendritic cell precursors, also expressing CD133 (CD133int),  
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other important phenotypic characteristics have to be taken into account:  
CD35-/CD34hi/HLA-DRhi/CD117hi/FSCint/SSCint/CD123-. Figure 3 presents a detailed 
immunophenotype of this compartment considering all the markers used in this 
protocol. 
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Fig. 3. Uncommitted bone marrow CD34+ HSC (red) immunophenotype. The remaining 
bone marrow CD34+ cell compartments are presented in grey 
2. Bone marrow CD34+ erythroid precursors 
Both CD34+ erythroid precursors and monocytic precursors express CD35. The two 
CD34+ subpopulations can be distinguished in this protocol by the expression of CD117 
and HLA-DR. The erythroid precursors are CD117+/HLA-DRint and the monocytic 
precursors are CD117dim/-/HLA-DRhi. Moreover, the erythroid precursors are 
characterized by a dim expression of CD34, CD45 and CD44 (Figure 4). 
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Fig. 4. Erythroid-committed bone marrow CD34+ precursors (red) immunophenotype. The 
remaining bone marrow CD34+ cell compartments correspond to the grey events 
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It is worth mentioning that our previous studies with simultaneous staining of CD105 and 
CD35 proved that the two markers were co-expressed in the same subset of CD34+ bone 
marrow cells and CD35 appears slightly before CD105 (Figure 5)1. 
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Fig. 5. Expression of CD105 and CD35 in bone marrow erythroid lineage: uncommitted 
CD34+ cells (red), CD34+erythroid precursors (blue) and CD34- erythroid precursors (grey) 
3. Bone marrow CD34+ neutrophil precursors 
Neutrophil precursors show high reactivity to CD44 antigen, as the plasmacytoid 
dendritic cell precursors (CD44hi), but in the absence of CD123 marker. Other important 
immunophenotypic features of this CD34+ compartment are: CD133int/CD35-/HLA-
DRhi/CD117hi/CD45int/dim/FSChi/SSChi (Figure 6). 
4. Bone marrow CD34+ monocyte precursors 
Using this single-tube approach, the monocyte precursors are primarily identified by 
exclusion of all the other myeloid CD34+ precursors. Is noteworthy that a large 
percentage of monocyte-committed CD34+ precursors express CD35, being 
discriminated from CD34+ erythroid precursors by their CD117dim/-/HLA-DR+/CD45hi 
phenotype. Although classically the identification of this CD34+ subset was made 
focusing on the expression of CD64, this marker seems to be also present on CD34+ 
plasmacytoid and myeloid dendritic cell precursors. In line with this, CD35 might be a 
good option to the identification of CD34+ monocyte precursors. The immunophenotype 
of this population is depicted in Figure 7. 
5. Bone marrow CD34+ B cell precursors 
Even in the absence of an B-cell lineage specific marker, as CD19 or CD79a, CD34+ B 
cell precursors are clearly identified by the low expression of CD44 and CD45, along 
with low light scatter properties (Figure 8). 
                                                 
1 According to our experience, CD35 seems to be expressed earlier than CD105 and CD36 on erythroid 
committed CD34+ precursors, allowing a more accurate quantification of this subset. 
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Fig. 6. Neutrophil-committed bone marrow CD34+ precursors (red) immunophenotype. The 
remaining bone marrow CD34+ cell compartments are presented in grey 
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Fig. 7. Monocytic-committed bone marrow CD34+ precursors (red) immunophenotype. The 
remaining bone marrow CD34+ cell compartments are presented in grey 
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Fig. 8. B-cell-committed bone marrow CD34+ precursors (red) immunophenotype. The 
remaining bone marrow CD34+ cell compartments are presented in grey 
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6. Bone marrow CD34+ basophil precursors 
Our protocol allows the identification of basophil precursors using the classical markers 
and attending to the immunophenotype HLA-DR-/dim/CD123int/hi. Of note, this CD34+ 
subset presents the lowest expression of CD44 among all bone marrow myeloid CD34+ 
cells, being easy to differentiate this precursors from all the other myeloid precursors by 
using CD44 marker (Figure 9). 
7. Bone marrow CD34+ plasmacytoid dendritic cell precursors 
The plasmacytoid dendritic cell precursors are identified using the classical markers, as 
being HLA-DRhi/CD123hi/int. The most immature forms of this precursor express 
CD133 (CD133int). The immunophenotypic characteristics of this population are 
represented on Figure 10. 
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Fig. 9. Basophil-committed bone marrow CD34+ precursors (red) immunophenotype. The 
remaining bone marrow CD34+ cell compartments are presented in grey 
www.intechopen.com
 
Flow Cytometry – Recent Perspectives 
 
472 
FSC-A CD44 PB 
CD45 PO 
S
S
C
-A
 
S
S
C
-A
 
S
S
C
-A
 
CD34 PerCP Cy5.5 HLA-DR APCH7 
HLA-DR APCH7 
C
D
1
17
 P
E
 C
y
7
C
D
1
23
 P
E
 
S
S
C
-A
 
C
D
1
23
 P
E
 
C
D
1
33
 A
P
C
 
CD35 FITC CD123 PE
0                1E2                 1E3                1E4               1E5
0 
   
   
   
   
   
  1
E
2 
   
   
   
   
   
   
  1
E
3 
   
   
   
   
   
 1
E
4 
   
   
   
   
   
  1
E
5
0 
   
   
   
   
   
   
1E
2 
   
   
   
   
   
   
  1
E
3 
   
   
   
   
   
  1
E
4 
   
   
   
   
   
  1
E
5
0              1E2                 1E3              1E4             1E5
0                  1E2                       1E3                    1E4                    1E5 0                1E2                 1E3                1E4               1E5
0                1E2                  1E3                1E4               1E50                1E2                  1E3               1E4               1E5
0                  1E2                       1E3                    1E4                   1E5
0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
5
0
0
0
0
  
  
  
  
  
  
  
  
  
  
 1
0
0
0
0
0
  
  
  
  
2
0
0
0
0
0
0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
5
0
0
0
0
  
  
  
  
  
  
  
  
  
  
1
0
0
0
0
0
  
  
  
  
  
2
0
0
0
0
0
0 
   
   
   
   
   
   
1E
2 
   
   
   
   
   
   
  1
E
3 
   
   
   
   
   
  1
E
4 
   
   
   
   
   
  1
E
5
0 
   
   
   
   
   
   
1E
2 
   
   
   
   
   
   
  1
E
3 
   
   
   
   
   
  1
E
4 
   
   
   
   
   
  1
E
5
0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 5
0
0
0
0
  
  
  
  
  
  
  
  
  
  
  
1
0
0
0
0
0
  
  
  
  
  
 2
0
0
0
0
0
0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
5
0
0
0
0
  
  
  
  
  
  
  
  
  
  
  
1
0
0
0
0
0
  
  
  
  
  
2
0
0
0
0
0
0                 50000           100000         150000         200000          250000
 
Fig. 10. Plasmacytoid dendritic cell-committed bone marrow CD34+ precursors (red) 
immunophenotype. The remaining bone marrow CD34+ cell compartments are presented in 
grey 
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8. Bone marrow CD34+ mast cell precursors 
The classical markers for the identification of CD34+ mast cell precursors are included 
in our protocol, and these cells are CD117hi/HLA-DR-/int. This subset expresses high 
levels of CD44. Other immunophenotypic characteristics of this subset are illustrated in 
Figure 11. 
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Fig. 11. Mast cell-committed bone marrow CD34+ precursors (red) immunophenotype. The 
events in grey correspond to remaining whole bone marrow nucleated cells 
3.3 The maturation dynamic of bone marrow CD34+ hematopoietic stem cell  
The possibility of a multiparameter analysis in a single cell basis conduct to a broader 
knowledge on the immunophenotypic characteristics of bone marrow CD34+ compartments 
and how it varies along the differentiation through different hematological cell lineages. 
Figure 12 depicts the dynamic of the maturation of different bone marrow CD34+ cell 
compartments. 
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Fig. 12. Maturational dynamic of bone marrow CD34+ HSC. Uncommitted CD34+ cells are 
presented in red, lineage committed CD34+ cells are presented in blue and the lineage 
committed CD34- cells correspond to grey events 
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4. Conclusion 
The emergence of high-speed multi-parameter flow cytometers have given an important 
contribute to unveil the phenotypic characteristics of minor cell populations and/or 
populations without a known specific cell marker. 
Using flow cytometry to characterize bone marrow MSC directly (without in vitro cell 
culture) represents a great advantage by enabling an analysis closest to the physiologic 
conditions of the cells, excluding all the phenotypic alterations induced by factors present in 
the culture medium. Moreover, this direct analysis allows an accurate quantification of these 
cells in bone marrow. In addition, the strategy used for bone marrow can also be applied in 
MSC from other tissues, allowing their direct quantification and characterization. 
A broader knowledge about the immunophenotypic characteristics of the different 
compartments of bone marrow HSC could improve their identification, allow a more 
accurate quantification of those compartments, as well as shed light on the protein 
expression patterns in the earliest stages of maturation of each hematological cell lineage. 
Furthermore, a better knowledge of those protein expression patterns might contribute to 
the development of new strategies to identify aberrant phenotypes in hematological diseases 
affecting the more immature bone marrow cells compartments, which can be helpful in the 
classification of acute leukemias, diagnosis of myelodysplastic syndromes and detection of 
minimal residual disease. A more extensive understanding of the phenotype of CD34+ 
hematopoietic stem cells in the different maturational stages could also be useful to 
monitoring and investigate if different mobilization regimens have the capability of 
mobilizing distinct CD34+ hematopoietic stem cells subpopulations. 
Here, we presented a simple, quick and economic approach to identify and quantify the 
different bone marrow CD34+ HSC compartments.  
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